The new tirzepatide vs semaglutide muscle loss study does not establish a muscle-preservation winner. People taking tirzepatide lost more weight and more lean mass, which includes muscle, body water and organs. Once researchers accounted for weight loss, the lean-mass gap largely disappeared. That challenges a simple claim that one medicine harms muscle more. It does not prove the medicines have identical effects.

Tirzepatide vs semaglutide muscle loss: what changed

As of November 12, 2026, the day this article was written, a study published today in npj Exercise Medicine and Health adds a direct comparison from routine care. Researchers looked back at health records rather than assigning people to a medicine. That makes this an observational study: it can find links, but cannot establish what caused them.

The analysis included 7,965 adults with body-composition measurements before and after starting treatment: 6,196 taking semaglutide and 1,769 taking tirzepatide. Body composition means how much of the body is fat or other tissue. Researchers examined changes during the following 12 months.

The headline difference needs its second line:

Twelve-month comparison Tirzepatide minus semaglutide Meaning
Difference in percentage change from starting lean mass −2.1 percentage points Greater lean-mass decline with tirzepatide
After accounting for weight change and other measured patient differences −0.1 percentage points The remaining gap was close to zero

These are percentage-point differences in lean-mass change, not percentages of muscle lost. For the adjusted result, the 95% confidence interval, a range showing statistical uncertainty, ran from −1.6 to +1.4 points. It included no difference and differences in either direction.

What the result means for someone taking either medicine

The authors' interpretation is straightforward: greater lean-mass loss accompanied greater overall weight loss. Their analysis did not find an extra tirzepatide-specific lean-tissue effect after accounting for that weight change.

At 12 months, among people who lost at least 5% of starting body weight, roughly one-fifth of the weight lost was lean mass with either medicine. That means a share of the weight that came off. It does not mean one-fifth of a person's starting muscle disappeared.

For someone taking semaglutide, the smaller unadjusted decline therefore does not establish better muscle protection. For someone taking tirzepatide, the larger decline does not establish a direct muscle-damaging effect. Neither conclusion follows from these records.

The broader tirzepatide versus semaglutide comparison covers the other differences a provider weighs. This new result adds one piece to that discussion; it cannot choose a prescription for an individual.

Why lean mass is not a muscle measurement

Most measurements came from bioelectrical impedance, which estimates body composition using a small electrical current. About two-thirds of patients had measurements from Tanita devices. DXA, a low-dose X-ray scan that separates fat, bone mineral and lean tissue, contributed to fewer than 1% of patients' measurements.

Those methods estimate tissue in different ways. Hydration can affect an electrical estimate, and the records did not always identify the device. Only 39% of patients had starting and follow-up readings from the same documented device type.

The authors found a similar between-drug pattern when they restricted the analysis to matching device types. That helps address one concern, but it cannot turn a lean-mass estimate into a direct muscle measurement.

The semaglutide muscle-loss guide explains the older trial evidence. A fall in lean mass and a fall in strength remain separate questions.

What this study does not prove

The 7,965 people represented just 1.2% of the wider group starting either medicine. People measured twice may receive closer monitoring than other patients. Even within this selected group, only a small fraction had a measurement near 12 months. The later results describe people who stayed in treatment and were measured again.

Food intake, exercise and other treatments were not fully captured. Adjusting the numbers cannot account for every difference between the groups. It also cannot prove the medicines are equivalent for muscle health.

Researchers did examine clinical notes for exercise limitations, falls and other function-related problems. Greater lean-mass loss went with more documented exercise limitation. But those notes were not standardized strength or performance tests. Pain-limited activity and differences in documentation could help explain the link. The study cannot show that lean-mass loss caused those difficulties.

What to watch next: strength alongside weight

As of November 12, 2026, the day this article was written, a separate Nature Medicine trial published November 9 provides a different kind of evidence. It randomly assigned 120 adults taking tirzepatide to resistance exercise, meaning training against weights or another load, or usual activity. Over 40 weeks, training reduced lean-tissue loss and improved measured strength compared with usual activity. It did not prevent all lean-tissue loss. The tirzepatide resistance-training trial explainer covers that study; it did not compare the two medicines.

For the comparison question, the next useful evidence would measure both medicines under the same conditions, with consistent devices and repeated strength tests. Daily function matters too: how someone walks, rises from a chair or manages ordinary tasks.

A clinical discussion can put those changes beside food intake, symptoms and the pace of weight loss. The tirzepatide exercise guide covers the wider activity discussion. A scan number alone cannot show how well someone is functioning.

Where a prescribed formulation fits

This health-record study does not establish results for a particular compounded preparation. Prescriptions in a record also cannot confirm every dose was taken.

Tirzepatide or semaglutide prescribed through Promise is dispensed by a licensed U.S. compounding pharmacy as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. As of November 12, 2026, the day this article was written, FDA's explanation of compounded drugs states that the agency does not review their safety, effectiveness or quality before marketing.

A licensed provider may still prescribe — that decision is between you and your doctor.

At Promise, a licensed provider reviews every request, and not everyone qualifies. The choice of medicine belongs in that review, with attention to health history, treatment goals, strength and function.